Yellow Cap
6 Months Through 4 Years of Age
by Pfizer-BioNTech COVID-19 Vaccination Status1
NUMBER OF PREVIOUS DOSES OF
VACCINE(S)*
0 Previous Doses Received†
Not previously vaccinated with any COVID-19 vaccine.
Pfizer-BioNTech
Dosing
Regimen, Dose, and Schedule
3 doses‡, 0.3 mL per dose
Dose 1: Week 0 Administer first dose
Dose 2: Administer 3 weeks after Dose 1
Dose 3: Administer ≥8 weeks after Dose 2
NUMBER OF PREVIOUS DOSES OF
VACCINE(S)*
1 Previous Dose Received
Pfizer-BioNTech
Dosing
Regimen, Dose, and Schedule
2 doses‡, 0.3 mL per dose
Dose 2: Administer ≥8 weeks after Dose 1
NUMBER OF PREVIOUS DOSES OF
VACCINE(S)*
2 to 4 Previous Doses
Pfizer-BioNTech
Dosing
Regimen, Dose, and Schedule
Single dose, 0.3 mL
Administer ≥8 weeks after receipt of the last previous dose of
*Previous doses of Pfizer-BioNTech
†Not previously vaccinated with any
‡For individuals turning from 4 to 5 years of age during the vaccination series, administer all doses with Pfizer-BioNTech
Yellow Cap
Immunocompromised Individuals
6 Months Through 4 Years of Age
by
Individuals 6 months through 4 years of age with certain kinds of immunocompromise§ should complete at least a 3-dose series with an age-appropriate dose and dosing schedule of a
- If previously not vaccinated, complete the 3-dose series with age-appropriate doses of
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula).ǁ - If previously vaccinated with 1 or 2 dose(s) of
Pfizer-BioNTech COVID-19 Vaccine (Original monovalent) and/or thePfizer-BioNTech COVID-19 Vaccine, Bivalent, complete the remaining dose(s) in the 3-dose series with age-appropriate doses ofPfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula). - If previously vaccinated with 3 or more doses, administer a single age-appropriate dose of
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) at least 2 months following the last previous dose.¶
§Certain kinds of immunocompromise refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
ǁDosing schedule for individuals 6 months through 4 years of age for
¶For immunocompromised individuals 6 months through 4 years of age, the last previous dose refers to the last dose of
The EUA Fact Sheet states that for individuals turning from 4 to 5 years of age during the vaccination series, administer all doses with Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) supplied in vials with yellow caps and labels with yellow borders.
Note: CDC Interim Clinical Considerations contain additional information and recommendations for HCPs vaccinating individuals transitioning from a younger to older age group2
- For additional information, please review CDC Interim Clinical Considerations
By clicking this link, you will be redirected to a website that is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of this site.
-
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (6 months through 11 years of age); BioNTech Manufacturing GmbH and Pfizer Inc.; December 08, 2023. -
Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States. November 03, 2023. Accessed November 07, 2023. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#immunocompromised
Eligible healthcare providers can order COVID-19 vaccines directly from Pfizer*
Learn about ordering vaccines through Pfizer Prime online or by calling 1-800-533-4535.
Blue Cap
5 Through 11 Years of Age
Irrespective of COVID-19 Vaccination Status1
A single dose at 0.3 mL per dose
If previously vaccinated, administer ≥2 months after receipt of last previous dose of
*COVID-19 vaccine refers to the monovalent COVID-19 vaccines that encode the spike protein of the original SARS-CoV-2 and the bivalent COVID-19 vaccines encoding the spike protein of original SARS-CoV-2 and of the Omicron-variant lineages BA.4 and BA.5 that are no longer authorized for use in the United States.
Blue Cap
Immunocompromised Individuals
5 Through 11 Years of Age
by Pfizer-BioNTech
Individuals 5 through 11 years of age with certain kinds of
immunocompromise† should complete at least a 3-dose series with an
age-appropriate dose and dosing schedule of a
-
If previously not vaccinated, complete the 3-dose series with
age-appropriate doses of
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula).‡ -
If previously vaccinated with 1 or 2 dose(s) of
Pfizer-BioNTech COVID-19 Vaccine (Original monovalent) and/or thePfizer-BioNTech COVID-19 Vaccine, Bivalent, complete the remaining dose(s) in the 3-dose series with age-appropriate doses ofPfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula). -
If previously vaccinated with 3 or more doses, administer a single
age-appropriate dose of
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) at least 2 months following the last previous dose.§
†Certain kinds of immunocompromise refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
‡Dosing schedule for individuals 5 through 11 years of age for Pfizer-BioNTech
§For immunocompromised individuals 5 through 11 years of age, the last previous dose refers to the last dose of a
Note: CDC Interim Clinical Considerations contain additional information and recommendations for HCPs vaccinating individuals transitioning from a younger to older age group2
-
For additional information, please review CDC Interim Clinical Considerations
By clicking this link, you will be redirected to a website that is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of this site.
-
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (6 months through 11 years of age); BioNTech Manufacturing GmbH and Pfizer Inc.; December 08, 2023. -
Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States. November 03, 2023. Accessed November 07, 2023. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#immunocompromised
Eligible healthcare providers can order COVID-19 vaccines directly from
Pfizer*
Learn about ordering vaccines through Pfizer Prime online or by calling 1-800-533-4535.